Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy
Jonathan I. Silverberg(George Washington University), Raj Chovatiya(Rosalind Franklin University of Medicine and Science), J.Q. Del Rosso(Valley Hospital Medical Center), Masahiro Kamata, Bülent Akmaz(Almirall (Spain)), Amy S. Paller(Northwestern University), Gaia Gallo(Eli Lilly (United States)), Thomas Bieber(CK-CARE), Marta Casillas(Eli Lilly (United States)), Erin Johansson(Eli Lilly (United States)), L. Puig(Universitat Autònoma de Barcelona), Linda Stein Gold(Henry Ford Health System), Tristan Curteis(Costello Medical Consulting (United Kingdom)), Marni Wiseman(University of Manitoba), Khaled Ezzedine(Hôpitaux Universitaires Henri-Mondor), Alan D. Irvine(Trinity College Dublin), Lisa A. Beck(University of Rochester Medicine), Peter Foley(The University of Melbourne), Andrei Karlsson(Costello Medical Consulting (United Kingdom)), M. Dossenbach
Cited by 24
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k